Inflammatory & Autoimmune

Michael George, MBBS, MRCP, MFPM, is the Global Therapeutic Area Head at Fortrea. 

His areas of expertise include global strategic clinical drug development and portfolio and program management across multiple therapeutic areas, including immune-mediated inflammatory diseases (IMIDs), cardiovascular and metabolic diseases and women’s health. 

He has more than 25 years of experience in the pharmaceutical and CRO industry, having held numerous posts of increasing seniority across all phases of clinical drug development in various therapeutic areas and pharmacovigilance with both regional and global responsibility. At Fortrea, Michael is responsible for medical portfolio oversight, executive governance and clinical business development. He has authored several articles in the areas of IMID development, hypertension, heart failure, diabetic retinopathy and neuro-endocrine modulation.

Maixing Ai, MD, is a Senior Medical Director, based in Princeton, NJ, U.S. Dr. Ai is a trained immunologist/rheumatologist with more than 22 years of clinical practice. He has extensive experience managing different immunologic/rheumatologic disorders, including rheumatoid arthritis, lupus, inflammatory bowel disease and psoriasis. 

Dr. Ai has more than 16 years of pharmaceutical and CRO industrial experience. He has experience with many clinical trials on NSAIDs, DMARDs, small molecules and biologics in autoimmune diseases. He has also worked on cell and gene therapies in autoimmune disease and musculoskeletal disease, with hands-on experience in cell therapies for lupus, rheumatoid arthritis and systemic sclerosis. 

Since joining Fortrea (formerly Labcorp/Covance), Dr. Ai has worked with many biotech companies and global pharmaceutical companies. His experience also includes Phase II-IV protocol design in many indications. 

Dr. Ai earned his medical doctorate degree from University of Luebeck, Luebeck, Schleswig-Holstein, Germany. He has authored/co-authored more than 60 papers/books in rheumatological topics.

Andrea Buschiazzo, MD, MBA, is a Senior Medical Director at Fortrea, a Board-Certified Rheumatologist and a Clinical Pharmacologist (University of Buenos Ares). At Fortrea, she offers therapeutic area expertise in inflammation and autoimmune diseases as well as global clinical development. 

Dr. Buschiazzo is based in Buenos Aires, Argentina, and provides medical leadership on projects teams, medical/scientific consultation and therapeutic expertise globally. She oversees study specific medical/safety monitoring activities, ensuring compliance with ethical, legal and regulatory standards as well as Fortrea and Sponsor SOPs, representing the Medical Affairs department in business development activities. 

She started her pharmaceutical career with Merck Sharp & Dohme in Medical & Scientific Affairs and Clinical Development, working in multiple therapeutic areas as an Associate Director before moving to a regional clinical development leader role at Servier for LATAM. Later, she worked at Kendle (then INC) as a Global Project Director and was responsible for successful development programs leading to registration of several innovative products before becoming a Managing Director at ICON. 

Dr. Buschiazzo has 33 years of experience in the pharmaceutical and CRO industry and 34 years in clinical practice. She completed a fellowship in autoimmune diseases at the Clinic Hospital in Barcelona. She published many articles and posted abstracts at the main Rheumatology Congresses (ACR/EULAR/SAR). 

She has provided global medical monitoring services and therapeutic advisory in almost all autoimmune diseases including Systemic Sclerosis, Rheumatoid Arthritis, Gout, Psoriatic Arthritis, Spondyloarthritis, Paget's disease, Sjögren's Syndrome, Vasculitis, Juvenile Arthritis, Osteoporosis, Osteoarthritis and Fibromyalgia. She has experience as Global Project Director and Medical Monitor for 10 Lupus studies, including Lupus Nephritis (Phase II-III) and the trials running prior to the approval of belimumab as the first biologic for SLE.

AnnMarie DiGiacomo is an Associate Director in Strategic Delivery & Growth for Infectious Diseases and Critical Care and is based in San Diego, California. AnnMarie has more than 25 years of clinical research experience including in academia, biotech/pharmaceutical and the CRO industry. Her expertise focuses on planning and execution of Infectious Disease, Vaccines and Critical Care with experience in clinical development from first in human to registration. She has held regional and global positions of increasing responsibility in program delivery, with primary focus in Interstitial Lung Disease (ILD) and more recently, COVID-19 trials. AnnMarie has provided significant contribution to the FDA approval of treatment for patients with Idiopathic Pulmonary Fibrosis. 

AnnMarie earned her bachelor's degree in biology from the University of Southern California. She joined our company in 2003.